EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

The G protein‐coupled receptor GPR 89 A is a novel potential therapeutic target to overcome cisplatin resistance in NSCLC Calu1 cells

Hale Guler Kara iD, Eda Dogan, Vildan Bozok, Cagdas Aktan, Ece Cakiroglu, Zuhal Eroglu, Duygu Aygunes Jafari, Kemal Sami Korkmaz, Serif Senturk iD, Buket Kosova

The FEBS Journal · 2025

DOI: 10.1111/febs.70099 ↗

At a glance

Journal article in The FEBS Journal, 2025. Written by Hale Guler Kara and 9 co-authors. Institution: Department of Medical Biology, Ege University School of Medicine, Izmir, Turkey. Major MEDLINE topics: Cisplatin, Drug Resistance, Neoplasm, Carcinoma, Non-Small-Cell Lung, Receptors, G-Protein-Coupled. Cited 8 times so far (Crossref); 45 references. The full text is freely available (open access, CC BY 4.0). Funded by: Türkiye Bilimsel ve Teknolojik Araştırma Kurumu, Ege University Research Foundation.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Lung cancer is the most frequently diagnosed cancer type worldwide and is characterised by its high metastatic potential. Standard therapy for nonsmall cell lung cancer (NSCLC) cases includes chemotherapy with the platinum‐based chemotherapeutic agent cisplatin. Although lung cancer cases respond well to cisplatin at the beginning of treatment, ~ 60% develop chemotherapy resistance during this process. In this study, a genome‐wide CRISPR‐Cas9‐based genetic screening approach was employed to identify genes that cisplatin‐resistant NSCLC Calu1 cells are more addicted to than sensitive cells. Cisplatin‐resistant Calu1 cells were generated by the dose escalation method, and genome‐wide CRISPR‐Cas9‐based genetic screening was performed with the Brunello CRISPR knockout library. Bioinformatics analyses of the obtained next‐generation sequencing data revealed 63 potential candidate genes responsible for cisplatin resistance, including G protein‐coupled receptor 89A ( GPR89A ), Poly(U) binding splicing factor 60 ( PUF60 ), NBAS subunit of NRZ tethering complex ( NBAS ) and GrpE like 1 , mitochondrial ( GRPEL1 ). The GPR89A protein is located in the Golgi cisterna and Golgi‐associated vesicle membrane, enables voltage‐gated anion channel activity, and is involved in intracellular pH reduction. Functional studies carried out with GPR89A ‐knockout cisplatin‐resistant Calu1 cells resulted in cell cycle arrest in the G2/M phase and increased polyploidy, and also prevented colony formation and cell migration. Cisplatin treatment, on the other hand, resulted in increased cell death by apoptosis upon cell cycle arrest in the S phase. In conclusion, this is the first study that identified GPR89A as a potential therapeutic target to overcome cisplatin resistance in NSCLC Calu1 cells.

Subjects

MeSH terms (MEDLINE)

CisplatinDrug Resistance, NeoplasmCarcinoma, Non-Small-Cell LungReceptors, G-Protein-CoupledLung NeoplasmsHumansCell Line, TumorCRISPR-Cas SystemsApoptosisAntineoplastic AgentsGene Expression Regulation, NeoplasticCell Proliferation

Author keywords

CRISPR‐Cas9GPR89ANSCLCcisplatin resistancegenetic screen

Substances

CisplatinReceptors, G-Protein-CoupledAntineoplastic Agents

Authors and institutions

  • Department of Medical Biology, Ege University School of Medicine, Izmir, Turkey.
  • Department of Medical Biology, Harran University School of Medicine, Sanliurfa, Turkey.
  • Department of Medical Biology, Bandirma Onyedi Eylul University School of Medicine, Balikesir, Turkey.
  • Izmir Biomedicine and Genome Center, Turkey.
  • Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir, Turkey.
  • Department of Bioengineering, Ege University School of Engineering, Izmir, Turkey.

ORCID profiles: Hale Guler Kara, Serif Senturk

Funding

  • Türkiye Bilimsel ve Teknolojik Araştırma Kurumu
  • Ege University Research Foundation

Cite

APA

Guler Kara, H., Dogan, E., Bozok, V., Aktan, C., Cakiroglu, E., Eroglu, Z., Aygunes Jafari, D., Korkmaz, K. S., Senturk, S., & Kosova, B. (2025). The G protein‐coupled receptor GPR 89 A is a novel potential therapeutic target to overcome cisplatin resistance in NSCLC Calu1 cells. The FEBS Journal. https://doi.org/10.1111/febs.70099

Vancouver

Guler Kara H, Dogan E, Bozok V, Aktan C, Cakiroglu E, Eroglu Z, et al. The G protein‐coupled receptor GPR 89 A is a novel potential therapeutic target to overcome cisplatin resistance in NSCLC Calu1 cells. The FEBS Journal. 2025. doi:10.1111/febs.70099

BibTeX
@article{GulerKara2025,
  author = {Guler Kara, Hale and Dogan, Eda and Bozok, Vildan and Aktan, Cagdas and Cakiroglu, Ece and Eroglu, Zuhal and Aygunes Jafari, Duygu and Korkmaz, Kemal Sami and Senturk, Serif and Kosova, Buket},
  title = {The G protein‐coupled receptor GPR 89 A is a novel potential therapeutic target to overcome cisplatin resistance in NSCLC Calu1 cells},
  journal = {The FEBS Journal},
  year = {2025},
  doi = {10.1111/febs.70099}
}
Start for free →